SEC Tracker
Get the app
ACET · XBRL financial data

Adicet Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ACET's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Research and development26,16724,759*23,89725,90126,25323,273*22,81428,42422,85325,036*17,48718,450
General and administrative6,6336,807*6,9746,9486,9007,470*7,0713,9685,0996,850*4,0833,851
Total operating expenses52,26231,566*30,87132,84933,15330,743*29,88532,39227,95231,886*21,57022,301
Other operating income (expense)—year only63515551*1222376154*1682
Operating income (loss)(52,262)(31,566)*(30,871)(32,849)(33,153)(30,743)*(29,885)(32,392)(27,952)(31,886)*(21,570)(22,301)
Interest expense10*2011*001224*2322
Other income (expense)(142)(101)*(61)(51)(54)(50)*(12)(223)(64)(130)*7(60)
Income tax expense (benefit)00*0000*0000*0143
Net income (loss)(49,885)(29,489)*(28,016)(29,901)(30,478)(28,727)*(28,214)(31,217)(26,856)(30,516)*(20,244)(21,358)
Earnings per share, basic USD per share(1.16)(0.68)*(0.35)(0.33)(0.34)(0.32)*(0.31)(0.34)(0.29)—(1.88)(1.99)
Earnings per share, diluted USD per share(1.16)(0.68)*(0.35)(0.33)(0.34)(0.32)*(0.31)(0.34)(0.29)—(1.88)(1.99)
Weighted average shares, basic thousands of shares42,98143,273*79,07290,63290,84690,850*91,07191,08691,086—10,74510,746
Weighted average shares, diluted thousands of shares42,98143,273*79,07290,63290,84690,850*91,07191,08691,086—10,74510,746
  • † Share count changed about 1/16 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ACET's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents183,257159,711247,589224,069105,48256,49528,13334,72029,09938,91836,24533,131
Short-term investments—0——96,583———————
Prepaid and other current assets2,6262,5612,7614,2844,2513,8333,1242,7773,3962,3962,4792,573
Total current assets185,883162,272250,350228,353206,316180,136153,563127,740106,494160,926140,071120,763
Property and equipment, net28,27326,77725,40724,04124,08822,52421,10819,54917,99416,53215,18314,028
Right-of-use asset18,18517,42416,64715,85515,05014,22813,38312,55511,90110,92710,2399,538
Goodwill00——————————
Total assets233,257207,295293,095268,842245,962220,219191,271162,972140,479192,355169,382148,166
Accounts payable4,0662,6252,5421,8992,5004,8304,4033,2924,2874,7392,9293,592
Total current liabilities19,76819,28717,46117,90419,39419,39216,44717,07918,94121,53118,29818,001
Lease liability, non-current18,66917,70316,71415,71114,92114,10213,26212,40511,64510,91010,1619,401
Total liabilities38,58037,12034,29133,73134,43133,61029,82529,60031,33733,14529,31728,028
Accumulated deficit(351,283)(380,772)(408,788)(438,689)(469,167)(497,894)(526,108)(557,325)(584,181)(614,697)(634,941)(656,299)
Total stockholders' equity194,677170,175258,804235,111211,531186,609161,446133,372109,142159,210140,065120,138
Total liabilities and equity233,257207,295293,095268,842245,962220,219191,271162,972140,479192,355169,382148,166
Common shares outstanding (cover page) thousands of shares43,16582,15482,17482,40182,40182,68682,71083,254153,2569,5969,3489,361
  • † Share count changed about 1/16 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ACET's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(49,885)(29,489)*(28,016)(29,901)(30,478)(28,727)*(28,214)(31,217)(26,856)(30,516)*(20,244)(21,358)
Stock-based compensation5,560*4,911*5,6796,0006,8003,773*3,1802,9002,5005,650*1,3031,400
Net cash from operating activities(21,238)*(23,486)*(22,849)(23,422)*(22,006)*(24,101)*(25,397)(26,633)*(22,307)*(20,909)*(21,490)(19,823)*
Purchases of property and equipment906*136*239302*401*176*1,49247*209*(10)*37202*
Net cash from investing activities(906)*(136)*(239)(302)*(96,581)*(22,120)*(2,861)32,953*16,836*(44,535)*18,87916,651*
Proceeds from issuing common stock0*0*19,2660*0*0*00*0*0*——
Net cash from financing activities(59)*76*110,966204*0*137*(104)267*(150)*75,232*(65)58*
Net change in cash(22,203)*(23,546)*87,878(23,520)*(118,587)*(46,084)*(28,362)6,587*(5,621)*9,788*(2,676)(3,114)*
  • † Share count changed about 1/16 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Adicet Bio33,131not reported(19,823)*9.4M1.7 quarters 10-QJun 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
Opus Genetics88,812755(11,950)*83.2M7.4 quarters 10-QJun 30, 2026
Acumen Pharmaceuticals53,075not reported(26,653)*72.3M3.4 quarters 10-QSep 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.